More News! 22 Nov 2018 First Drug for Rare Inflammation Syndrome Approved by FDA The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […] November 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […] February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […] July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […] May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2017 This British Biotech is buying its way into the Crowded NASH Space Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […] January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email